Histopathology
June 18, 2026 · via Europe PMC
Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next-generation sequencing in lung adenocarcinoma (LUAD).
Zhang Y, Zheng K, Tang Y, +8 more, Jiang L.
AI summary â for doctors, generated from the abstract only
A multicenter study found that a specific, detailed way of interpreting a routine immunohistochemistry stain (p53) can accurately predict TP53 gene mutation status in lung adenocarcinoma with over 90% accuracy, offering a much faster and cheaper alternative to genetic sequencing for this clinically important mutation that affects prognosis.
What was studied
A multicenter study of 221 lung adenocarcinoma patients, comparing a detailed, multi-parameter p53 immunohistochemistry scoring system (incorporating staining intensity, distribution, and cellular location) against actual TP53 gene mutation status determined by next-generation sequencing, to evaluate whether this routine, inexpensive stain could serve as an accurate surrogate for genetic testing.
Key findings
- Overall, p53 immunohistochemistry showed high agreement with TP53 mutation status, achieving 91.40% accuracy; a novel cutoff requiring 40% or more of cells showing the strongest (3+) nuclear staining predicted TP53 mutations with even higher accuracy (94.81%).
- Complete absence of p53 staining or staining in the cell's cytoplasm (rather than nucleus) strongly correlated with a specific type of mutation (truncating mutations, 92.31% concordance), while strong nuclear overexpression was linked to a different mutation type (missense mutations).
- TP53-mutant tumors showed distinct additional genetic patterns, including more frequent mutations in other specific cancer genes (RB1, MET, ERBB2, MYC, PTCH1) and fewer co-occurring mutations in another gene (STK11); survival analysis confirmed that p53 staining pattern reliably predicted prognosis similarly to actual TP53 mutation status.
Clinical relevance
The findings support using this detailed p53 immunohistochemistry scoring approach, particularly the newly proposed 40% cutoff, as an accurate, rapid, and cost-effective alternative to genetic sequencing for determining TP53 mutation status in lung adenocarcinoma patients, which could facilitate faster molecular classification and more timely prognostic and treatment decisions in routine practice.
Who should care
Limitations
This is a multicenter but still limited cohort study (221 patients), and while the correlation with mutation status was strong, the authors' proposed scoring system would benefit from further validation and standardization across different laboratories before widespread routine adoption.
A detailed way of interpreting a standard, inexpensive immunohistochemistry stain (p53) can accurately predict TP53 gene mutation status in lung adenocarcinoma with over 90% accuracy, offering a faster, cheaper alternative to genetic sequencing for this prognostically important mutation.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates â verify against the original source before acting on it.
Abstract
Objectives
TP53 mutations, prevalent in 50%-70% of lung adenocarcinoma (LUAD), are associated with poor prognosis and therapeutic resistance. This study aimed to evaluate the diagnostic accuracy of p53 immunohistochemistry (IHC) as a rapid and cost-effective alternative to next-generation sequencing (NGS) for TP53 mutation detection in LUAD patients.
Materials and methods
A multicentre cohort of 221 LUAD patients was analysed. TP53 mutation status was determined via NGS and compared with p53 IHC staining patterns. A multiparametric p53 IHC assessment system was established, integrating staining intensity, spatial distribution and subcellular localization data.
Results
p53 IHC demonstrated high concordance with TP53 mutation status, achieving an overall accuracy of 91.40% (Îșâ=â0.83). A novel â„40% cut-off for 3+ nuclear staining predicted TP53 mutations with 94.81% accuracy (Îșâ=â0.91). Complete p53 absence or cytoplasmic expression strongly correlated with truncating mutations (92.31% concordance), while missense mutations were linked to nuclear overexpression. TP53-mutant tumours exhibited distinct molecular profiles, including increased frequencies of RB1, MET, ERBB2, MYC and PTCH1 mutations, alongside reduced STK11 comutations. Kaplan-Meier survival analysis demonstrated that p53 IHC serves as a reliable surrogate marker for TP53 mutation status, offering significant prognostic value in LUAD patients.
Conclusion
p53 IHC, particularly using a â„40% cut-off at 3+ intensity, is an accurate and accessible surrogate for TP53 mutation detection in LUAD patients. This method facilitates rapid molecular stratification, optimal resource utilization and informed prognostic and therapeutic decision-making in routine pathology practice.
DOI
10.1111/his.70185
PMID
42315496
PMCID
PMC13441326
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed